Palisade Bio (PALI) Competitors $0.70 +0.06 (+8.70%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. NERV, BCDA, FLGC, ORGS, IPA, LPTX, AFMD, TRIB, BGXX, and APREShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Minerva Neurosciences (NERV), BioCardia (BCDA), Flora Growth (FLGC), Orgenesis (ORGS), ImmunoPrecise Antibodies (IPA), Leap Therapeutics (LPTX), Affimed (AFMD), Trinity Biotech (TRIB), Bright Green (BGXX), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Minerva Neurosciences BioCardia Flora Growth Orgenesis ImmunoPrecise Antibodies Leap Therapeutics Affimed Trinity Biotech Bright Green Aprea Therapeutics Minerva Neurosciences (NASDAQ:NERV) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation. Is NERV or PALI more profitable? Minerva Neurosciences' return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% Palisade Bio N/A -148.51%-115.16% Does the media refer more to NERV or PALI? In the previous week, Minerva Neurosciences' average media sentiment score of 0.00 equaled Palisade Bio'saverage media sentiment score. Company Overall Sentiment Minerva Neurosciences Neutral Palisade Bio Neutral Which has preferable valuation and earnings, NERV or PALI? Palisade Bio has higher revenue and earnings than Minerva Neurosciences. Palisade Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.197.55Palisade Bio$250K12.31-$12.30M-$10.92-0.06 Do insiders and institutionals hold more shares of NERV or PALI? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 8.6% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 3.3% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate NERV or PALI? Minerva Neurosciences currently has a consensus target price of $5.00, indicating a potential upside of 248.43%. Palisade Bio has a consensus target price of $23.00, indicating a potential upside of 3,185.71%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, NERV or PALI? Minerva Neurosciences has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Does the MarketBeat Community favor NERV or PALI? Minerva Neurosciences received 337 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 56.15% of users gave Minerva Neurosciences an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34756.15% Underperform Votes27143.85% Palisade BioOutperform Votes1050.00% Underperform Votes1050.00% SummaryMinerva Neurosciences and Palisade Bio tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.08M$2.85B$5.30B$7.16BDividend YieldN/A1.53%4.87%4.06%P/E Ratio-0.0529.2922.8717.50Price / Sales12.31415.51356.4785.03Price / CashN/A168.6838.1634.64Price / Book0.043.456.233.82Net Income-$12.30M-$72.06M$3.20B$247.19M7 Day PerformanceN/A-13.37%-8.27%-7.19%1 Month Performance-12.37%-20.61%-3.22%-9.97%1 Year Performance-87.83%-34.32%3.38%-7.26% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio1.5074 of 5 stars$0.70+8.7%$23.00+3,185.7%-89.0%$3.08M$250,000.00-0.0510NERVMinerva Neurosciences2.4114 of 5 stars$1.70-6.1%$5.00+194.1%-39.4%$11.89MN/A-3.869Analyst ForecastBCDABioCardia2.707 of 5 stars$2.54-9.3%$25.00+884.3%-64.4%$11.89M$58,000.00-0.6140Gap UpHigh Trading VolumeFLGCFlora Growth3.2466 of 5 stars$0.61-6.9%$5.00+726.4%-80.9%$11.76M$59.51M-0.46280Positive NewsGap UpORGSOrgenesisN/A$2.44-27.6%N/AN/A$11.71M$662,000.000.00150High Trading VolumeIPAImmunoPrecise Antibodies1.82 of 5 stars$0.38-4.0%$4.00+962.4%-76.6%$11.70M$24.07M-0.4880Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLPTXLeap Therapeutics2.1788 of 5 stars$0.31-3.6%$4.92+1,511.5%-87.6%$11.69MN/A-0.1640Short Interest ↓Gap DownAFMDAffimed4.2267 of 5 stars$0.72-7.4%$13.50+1,766.7%-90.5%$11.64M$877,000.000.00200Analyst ForecastShort Interest ↓News CoverageGap UpTRIBTrinity Biotech0.8856 of 5 stars$0.57-11.1%N/A-71.9%$11.57M$59.13M-0.25480BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownAPREAprea Therapeutics3.1446 of 5 stars$2.04-2.4%$15.50+659.8%-71.5%$11.20M$580,000.00-0.737Short Interest ↑Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies NERV Alternatives BCDA Alternatives FLGC Alternatives ORGS Alternatives IPA Alternatives LPTX Alternatives AFMD Alternatives TRIB Alternatives BGXX Alternatives APRE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | SponsoredControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
